EULAR: New data for three anti-TNF biosimilar development candidates

10 June 2015

US biotech firm Biogen (Nasdaq: BIIB) and its South Korean joint venture Samsung Bioepis today released positive results from their anti-TNF biosimilar portfolio are being presented at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, June 10–13, 2015.

Highlights include results from separate head-to-head Phase III studies showing clinical comparability of SB4 (etanercept) and SB2 (infliximab), which are biosimilar development candidates to their respective reference products Amgen’s (Nasdaq: AMGN) Enbrel and Johnson & Johnson’s (NYSE: JNJ) Remicade. Also being presented are equivalence data from a Phase I pharmacokinetic (PK) study comparing SB5 (adalimumab), a biosimilar development candidate, with the reference product AbbVie’s (NYSE: ABBV) Humira. These results profile a promising anti-TNF biosimilar portfolio for the two companies.

SB4 data highlights
The 24-week data from a Phase III study comparing SB4 with the etanercept reference product Enbrel in patients with moderate to severe rheumatoid arthritis, despite methotrexate therapy, showed equivalence in terms of clinical efficacy and safety.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK